108 related articles for article (PubMed ID: 15610401)
1. Clinical and immunological effects of azithromycin in Behçet's disease.
Mumcu G; Ergun T; Elbir Y; Eksioglu-Demiralp E; Yavuz S; Atalay T; Direskeneli H
J Oral Pathol Med; 2005 Jan; 34(1):13-6. PubMed ID: 15610401
[TBL] [Abstract][Full Text] [Related]
2. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behçet's disease.
Mumcu G; Inanç N; Özdemir FT; Tulunay A; Ekşioğlu-Demiralp E; Ergun T; Direskeneli H
Int J Dermatol; 2013 Dec; 52(12):1561-6. PubMed ID: 23879671
[TBL] [Abstract][Full Text] [Related]
3. The assessment of oral health-related quality of life by factor analysis in patients with Behcet's disease and recurrent aphthous stomatitis.
Mumcu G; Hayran O; Ozalp DO; Inanc N; Yavuz S; Ergun T; Direskeneli H
J Oral Pathol Med; 2007 Mar; 36(3):147-52. PubMed ID: 17305636
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.
Durmazlar SP; Ulkar GB; Eskioglu F; Tatlican S; Mert A; Akgul A
Int J Dermatol; 2009 Mar; 48(3):259-64. PubMed ID: 19261013
[TBL] [Abstract][Full Text] [Related]
6. Oral health related quality of life is affected by disease activity in Behçet's disease.
Mumcu G; Inanc N; Ergun T; Ikiz K; Gunes M; Islek U; Yavuz S; Sur H; Atalay T; Direskeneli H
Oral Dis; 2006 Mar; 12(2):145-51. PubMed ID: 16476035
[TBL] [Abstract][Full Text] [Related]
7. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
[TBL] [Abstract][Full Text] [Related]
8. Behçet's disease in Lebanon: report of 100 cases.
Ghayad E; Tohme A
J Med Liban; 1995; 43(1):2-7. PubMed ID: 8676358
[TBL] [Abstract][Full Text] [Related]
9. A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis.
Mumcu G; Sur H; Inanc N; Karacayli U; Cimilli H; Sisman N; Ergun T; Direskeneli H
J Oral Pathol Med; 2009 Nov; 38(10):785-91. PubMed ID: 19614861
[TBL] [Abstract][Full Text] [Related]
10. Plasma thrombomodulin levels in patients with Behçet's disease.
Düzgün N; Ayaşlioğlu E; Tutkak H; Sahin M; Aydintuğ O; Olmez U
Rheumatol Int; 2003 May; 23(3):130-3. PubMed ID: 12739044
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease.
Lee JH; Jung JY; Bang D
J Eur Acad Dermatol Venereol; 2008 May; 22(5):590-5. PubMed ID: 18093111
[TBL] [Abstract][Full Text] [Related]
12. Late-onset Behçet's disease does not correlate with indolent clinical course: report of seven Taiwanese patients.
Tsai J; Chen GS; Lu YW; Wu CS; Lan CC
J Eur Acad Dermatol Venereol; 2008 May; 22(5):596-600. PubMed ID: 18266686
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha treatment of Behçet's disease.
O'Duffy JD; Calamia K; Cohen S; Goronzy JJ; Herman D; Jorizzo J; Weyand C; Matteson E
J Rheumatol; 1998 Oct; 25(10):1938-44. PubMed ID: 9779847
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease.
Akman A; Sallakci N; Coskun M; Bacanli A; Yavuzer U; Alpsoy E; Yegin O
Br J Dermatol; 2006 Aug; 155(2):350-6. PubMed ID: 16882174
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study.
Alpsoy E; Donmez L; Onder M; Gunasti S; Usta A; Karincaoglu Y; Kandi B; Buyukkara S; Keseroglu O; Uzun S; Tursen U; Seyhan M; Akman A
Br J Dermatol; 2007 Nov; 157(5):901-6. PubMed ID: 17711526
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with colchicine and Herba Taraxaci (Tarazacum mongolicum Hand.-Mazz.) attenuates Behcet's disease-like symptoms in mice and influences the expressions of cytokines.
Sohn S; Bang D; Lee SI; Kim YA; Lee ES; Ha JY; Kim JH; Choi SY; Lee S
Int Immunopharmacol; 2003 May; 3(5):713-21. PubMed ID: 12757740
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Behçet's disease.
Kötter I; Dürk H; Saal J; Fierlbeck G; Pleyer U; Ziehut M
Ger J Ophthalmol; 1996 Mar; 5(2):92-7. PubMed ID: 8741153
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of Behçet's syndrome with colchicine].
Pacor ML; Nicolis F; Peroli P; Urbani G; Cortina P; Corrocher R; Lunardi C
Riv Eur Sci Med Farmacol; 1989 Jun; 11(3):257-61. PubMed ID: 2640046
[TBL] [Abstract][Full Text] [Related]
19. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease.
Ben Ahmed M; Houman H; Miled M; Dellagi K; Louzir H
Arthritis Rheum; 2004 Jul; 50(7):2291-5. PubMed ID: 15248229
[TBL] [Abstract][Full Text] [Related]
20. [Behçet's disease. Apropos of 32 cases].
Bitar E; Ghayad E; Ghoussoub K; Sinno W; Chams H; Khoury A; Baloglou P; Kallab K; Halaby C; Chemaly R
Rev Rhum Mal Osteoartic; 1986 Nov; 53(11):621-4. PubMed ID: 3616444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
